AgomAb Therapeutics NV (AGMB)Healthcare | Biotechnology | Antwerp, Belgium | NasdaqGS
13.17 USD
-0.67
(-4.841%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 13.17 |
Hot Take ↕ | Aug. 22, 2026, 2:54 a.m. EDT
The immediate outlook is flat due to a lack of price momentum and a statistically weak short-term forecast, while the long-term picture remains neutral because the company lacks a multi-year price history to confirm business quality despite its strong balance sheet. The stock offers no income, making it purely a speculative bet on future clinical trials rather than a value or yield play. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.100587 |
| AutoETS | 0.102815 |
| MSTL | 0.106905 |
| AutoTheta | 0.152911 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.64 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.599 |
| Excess Kurtosis | 0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.429 |
| Market Cap | 648,595,840 |
| Forward P/E | -6.36 |
| Website | https://www.agomab.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.10102391 |
| Address1 | Posthoflei 1/6 |
| All Time High | 17.82 |
| All Time Low | 8.75 |
| Ask | 16.81 |
| Ask Size | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 135,000 |
| Average Daily Volume3 Month | 110,804 |
| Average Volume | 110,804 |
| Average Volume10Days | 135,000 |
| Bid | 10.01 |
| Bid Size | 2 |
| Book Value | 2.6415083 |
| City | Antwerp |
| Country | Belgium |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.17 |
| Current Ratio | 12.878 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 14.2 |
| Day Low | 12.84 |
| Debt To Equity | 0.429 |
| Display Name | AgomAb Therapeutics |
| Ebitda | -65,561,332 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.001 |
| Enterprise Value | 458,964,256 |
| Eps Current Year | -1.852 |
| Eps Forward | -2.0705 |
| Eps Trailing Twelve Months | -1.58 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.1688 |
| Fifty Day Average Change | 0.0011997223 |
| Fifty Day Average Change Percent | 0.000091103386 |
| Fifty Two Week Change Percent | -10.102391 |
| Fifty Two Week High | 17.82 |
| Fifty Two Week High Change | -4.6499996 |
| Fifty Two Week High Change Percent | -0.26094276 |
| Fifty Two Week Low | 8.75 |
| Fifty Two Week Low Change | 4.42 |
| Fifty Two Week Low Change Percent | 0.50514287 |
| Fifty Two Week Range | 8.75 - 17.82 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,770,388,200,000 |
| Float Shares | 11,452,075 |
| Forward Eps | -2.0705 |
| Forward P E | -6.3607826 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 62 |
| Fullday Change | -0.67 |
| Fullday Change Percent | -4.84104 |
| Fullday Price | 13.17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05895 |
| Held Percent Institutions | 0.53631 |
| Implied Shares Outstanding | 49,247,975 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-02-06 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium. |
| Long Name | AgomAb Therapeutics NV |
| Market | us_market |
| Market Cap | 648,595,840 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_563168576 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -81,604,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 686,516,771 |
| Number Of Analyst Opinions | 6 |
| Open | 13.84 |
| Operating Cashflow | -56,726,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 32 3 318 91 70 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 13.17 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 13.84 |
| Price Eps Current Year | -7.1112313 |
| Price Hint | 2 |
| Price To Book | 4.985788 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.554 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | -0.67 |
| Regular Market Change Percent | -4.84104 |
| Regular Market Day High | 14.2 |
| Regular Market Day Low | 12.84 |
| Regular Market Day Range | 12.84 - 14.2 |
| Regular Market Open | 13.84 |
| Regular Market Previous Close | 13.84 |
| Regular Market Price | 13.17 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 252,919 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 49,247,975 |
| Shares Percent Shares Out | 0.0191 |
| Shares Short | 941,121 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,241,839 |
| Short Name | AgomAb Therapeutics NV |
| Short Percent Of Float | 0.0231 |
| Short Ratio | 10.22 |
| Source Interval | 15 |
| Symbol | AGMB |
| Target High Price | 60.0 |
| Target Low Price | 28.0 |
| Target Mean Price | 37.66667 |
| Target Median Price | 34.5 |
| Total Cash | 251,976,992 |
| Total Cash Per Share | 6.181 |
| Total Debt | 1,139,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.58773 |
| Two Hundred Day Average Change | 0.58226967 |
| Two Hundred Day Average Change Percent | 0.046256922 |
| Type Disp | Equity |
| Volume | 252,919 |
| Website | https://www.agomab.com |
| Zip | 2,600 |